EM2, a Natural Product MST1/2 Kinase Activator, Suppresses Non‐Small Cell Lung Cancer via Hippo Pathway Activation
Advanced Science · 2026
DOI: 10.1002/advs.202510508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Siyu Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangz…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This project was supported financially by grants from the National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Planning Project of Guangzhou City.
Abstract (Originalsprache)
Lung cancer, 85% of which is non‐small cell lung cancer (NSCLC), is the cancer with the highest incidence and mortality rate worldwide. Despite recent advancements in therapeutic approaches, the efficacy of conventional radiotherapy and chemotherapy remains suboptimal, highlighting the urgent need for more effective treatment strategies. Dysregulation of kinases MST1 and MST2 (MST1/2) is implicated in the progression of NSCLC, positioning MST1/2 as a potential therapeutic target. However, no high‐selectivity and high‐efficacy MST1/2 activator is identified to date. In this study, by using computer‐aided virtual screening combined with cell experiments, EM2 is identified as a promising MST1/2‐binding candidate. Subsequent experimental validation demonstrates that EM2 significantly suppresses the proliferation, migration, and invasion of NSCLC cells by directly targeting MST1/2 and enhancing its kinase activity, thereby activating the Hippo signaling pathway and reducing nuclear translocation of the downstream effector YAP. Both in vivo xenograft models and organoid models demonstrates that EM2 effectively suppresses NSCLC tumor growth. In summary, this study not only reaffirms MST1/2 as a viable therapeutic target for NSCLC but also provides compelling experimental evidence supporting EM2 as a highly effective and promising anti‐cancer agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, China.
- Department of Anesthesiology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
- Institute of Traditional Chinese Medicine & Natural Products, Guangdong Province Key 4 Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 511443,…
- State Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangzhou Key Laboratory of Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, 510632, China.
- School of Pharmacy, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Yubo Zhang
Förderung
- This project was supported financially by grants from the National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Planning Project of Guangzhou City
- Clinical Characteristic Technology Project of Guangzhou Municipal Health Commission, China
- Guangdong Special Support Plan" Provincial Health Commission (Health Talent) Project, China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Yang, S., Xie, H., Lin, Q., Zhou, L., Liu, J., Fang, Z., Tang, Z., Yuan, R., Su, J., Li, S., Wang, W., Pan, M., Wang, H., Dai, X., Wang, G., & Zhang, Y. (2026). EM2, a Natural Product MST1/2 Kinase Activator, Suppresses Non‐Small Cell Lung Cancer via Hippo Pathway Activation. Advanced Science. https://doi.org/10.1002/advs.202510508
Vancouver
Yang S, Xie H, Lin Q, Zhou L, Liu J, Fang Z, et al. EM2, a Natural Product MST1/2 Kinase Activator, Suppresses Non‐Small Cell Lung Cancer via Hippo Pathway Activation. Advanced Science. 2026. doi:10.1002/advs.202510508
BibTeX
@article{Yang2026,
author = {Yang, Siyu and Xie, Huayan and Lin, Qiang and Zhou, Liujin and Liu, Junxi and Fang, Zekai and Tang, Ziling and Yuan, Ruijie and Su, Jinxuan and Li, Sijia and Wang, Wenlin and Pan, Mingyu and Wang, Hao and Dai, Xiaoyong and Wang, Guocai and Zhang, Yubo},
title = {EM2, a Natural Product MST1/2 Kinase Activator, Suppresses Non‐Small Cell Lung Cancer via Hippo Pathway Activation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202510508}
}
EUVIMED